PTGS2 and breast cancer: In the TCGA BC cohort overall survival data showed a better prognosis for high COX-2 patients (p=0.0011, HR 2.452 [1.428-4.208] but not for PIK3CA mutated patients (Supplementary Figure S4A and S4B).